Enric García Rey

Hematólogo
Hospital Sant Joan de Déu Barcelona
Médico adjunto del Laboratorio, Servicio de Transfusión Hospitalaria.

La docencia es compartir conocimientos y experiencias.

Experiencia docente

Procuro dar a conocer el trabajo que se realiza en mi ámbito laboral.

Actividad relacionada

  • Participarte en la elaboración y actualización de contenidos en los protocolos a seguir en el Servicio de Transfusión Hospitalaria.

Investigació

  • Colaborador en I-Clinical Trial: IG1002. EudraCT: 2011-001598-25. A multicenter randomized controlled study evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmapheresis with infusion human albumin combined with intravenous immunoglobulin in patients with mild –moderate Alzheimer’s Disease. Institut Grifols. S. A. Principal Investigator: Dra. Mercè Boada.
  • Colaborador en II-Clinical Trial: MOZ15609/DFI12860. EudraCT :2010-19340-40. A phase1/2 combined dose ranging and randomized, open label, comparative study of the efficacy and safety of Plerixaflor in addition to standard regimens for mobilization of hematopoietic stem cells into peripheral blood and subsequent collection by apheresis, versus standard mobilization regimens alone pediatric patients, aged 1 to <18 years, with solid tumors eligible for autologous transplants. Genzyme Europe BV. Principal Investigator: Dra. Susana Rives
  • Colaborador en III-Clinical Trial: CCTL019B2202 (substudy CCTL019B2206). EudraCT: 2013-003205-25. A Phase II, single arm. Multicenter trial to determine the efficacy and safety of CTL019 in pediatric with relapsed and refractory B-cell acute lymphoblastic leukemia (Substudy: A multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial). Sponsor: Novartis Farmacéutica S.A. Principal Investigator: Dra. Susana Rives
  • Colaborador en IV Clinical Trial: Código protocolo: GC P#05.01.020 EudraCT Number: 2016-000704-28. "A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies." Promotor: Gamida Cell Ltd.